Sai Life Sciences share price, P/E, ROE & financials

On 6 Nov 2026, Sai Life Sciences was priced at ₹1,785.10, or 101.5× trailing earnings, against an industry P/E of 52.8×. Sales grew 21% a year over 3 years, with ROCE of 18% and ROE of 15%. Debt is 0.12× equity. It is a mid-cap company with a market cap of ₹37,929 Cr, the largest of 18 Diagnostics & Research companies by market cap; the shares rose 73% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Jun 2026.How we calculate this

past year

Open: ₹1,655.10
Day high: ₹1,814.90
Day low: ₹1,614.90
Prev. close: ₹1,594.50
Volume: 1.3 Cr

Health check

3 good · 1 fair · 2 to check

ReturnsAhead
+72.7% over a year, better than 7 of 7 peers.
Price tagPricier
P/E 101.5 vs industry 52.8.
GrowthStrong
Sales +21.3%, profit +226.8% a year over 3 years.
ProfitabilityAverage
ROCE 18.1% vs peer median 19.1%.
Balance sheetSolid
Debt 0.12× equity, interest covered 12.9×, Piotroski 7 of 9.
Red flags1 to check
P/E of 101.5 against an industry P/E of 52.8.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Diagnostics & Research

17 listed peers. Screen the industry

Mid cap

₹37,929 Cr, the largest of 18 in its industry.

Market sensitivity

Measuring against the NIFTY 50…

Key metrics

Last 12 months to Jun 2026: sales ₹2,250 Cr · profit ₹362 Cr

Market cap: ₹37,929 Cr; Mid cap
P/E: 101.5; Industry 52.8
Price to book: 15.22; Peers 7.17
Dividend yield: 0.00%
ROE: 15.1%; Peers 17.7%
ROCE: 18.1%; Peers 19.1%
Debt to equity: 0.12; Debt ₹288 Cr
EPS (TTM): ₹17.58; Face value ₹1
OPM (TTM): 28.7%; Net margin 16.1%
Sales growth: +11.7%; Latest quarter vs a year ago
Profit growth: +21.2%; Latest quarter vs a year ago
Price to sales: 16.85; EV/EBITDA 56.7

Strengths

Quarterly profit up 21.2% on a year ago.
Positive operating cash flow in each of the last 4 years.

Risks to check

P/E of 101.5 against an industry P/E of 52.8.

Derived automatically from reported figures. Not a recommendation.

About Sai Life Sciences

Sai Life Sciences Limited operates as a contract research, development, and manufacturing organization (CRDMO) in India and internationally. It offers medicinal chemistry, pharmacokinetics, clinical and commercial manufacturing, and process development services. The company was formerly known as SAI Advantium Pharma Limited and changed its name to Sai Life Sciences Limited in July 2006. Sai Life Sciences Limited was incorporated in 1999 and is…

Headquarters: Hyderabad
Employees: 5,224
Sector: Healthcare
ISIN: INE570L01029
Website: sailife.com

Price range

52 weeks

₹783.85₹1,814.90

Today

₹1,614.90₹1,814.90

Avg volume (3M): 8.3 L
1-year return: plus 72.7%
From 52-week high: minus 1.6%

Analyst consensus

7 analysts

Strong buyMean target ₹1,579.43 11.5%

The mean target is below today’s price.

Target range, with today’s price

Low ₹1,500.00High ₹1,620.00

Today’s price ₹1,785.10 is above the highest analyst target.

Consensus from Yahoo Finance. Not a recommendation.

Peers · Diagnostics & Research

Compare with peers Screen the whole industry

Company
SAILIFESai Life Sciences	1,785.10	plus 11.95%	37,929	101.5	15.22	18.1%	15.1%	28.7%	21.3%	226.8%	0.00%	plus 72.7%
LALPATHLABDr. Lal Path Labs	1,970.00	plus 0.16%	32,941	56.5	11.99	25.7%	22.6%	30.2%	11.1%	28.3%	1.02%	plus 24.7%
SYNGENESyngene International	417.30	plus 0.77%	16,772	90.3	3.46	8.3%	3.9%	25.7%	5.4%	−12.0%	0.30%	minus 36.0%
VIJAYAVijaya Diagnostic Centre	1,468.60	plus 2.15%	15,126	74.4	14.29	19.1%	21.2%	43.1%	21.0%	26.9%	0.14%	plus 40.2%
METROPOLISMetropolis Healthcare	568.75	minus 0.39%	11,803	52.8	7.17	15.7%	14.6%	21.7%	12.7%	10.0%	0.35%	plus 12.5%
THYROCAREThyrocare Technologies	493.10	plus 0.68%	7,848	55.0	14.75	33.8%	26.4%	32.2%	16.7%	36.2%	1.89%	plus 8.3%
VIMTALABSVimta Labs	496.45	minus 2.14%	2,219	27.9	4.52	21.0%	17.7%	34.7%	8.9%	17.2%	0.40%	minus 23.3%
SURAKSHASuraksha Diagnostic	333.55	plus 0.68%	1,737	48.5	7.07	14.7%	14.1%	21.8%	17.7%	70.3%	0.15%	plus 2.2%
Median of 7 peers	–	0.68%	11,803	55.0	7.17	19.1%	17.7%	30.2%	12.7%	26.9%	0.35%	8.3%

Quarterly results

Consolidated, ₹ crore

SalesSelect a row below to chart it

Mar 25	Jun 25	Dec 25	Mar 26	Jun 26
580	496	556	602	554
–	–	–	+3.9%	+11.7%
422	375	369	426	406
158	121	188	177	148
27.2%	24.4%	33.8%	29.3%	26.7%
9.6	9.9	8.4	15.5	3.5
10.9	12.4	9.7	7.8	7.6
37.5	37.7	44.1	45.3	45.9
–	–	−8.3	0.3	–
119	80.7	134	139	98
25.7%	25.1%	25.2%	25.1%	25.2%
88.3	60.5	100	104	73.3
–	–	–	+18.1%	+21.2%
4.14	2.83	4.71	4.87	3.42

Sep 25 not reported by the data source.

Profit & loss

Yearly, ₹ crore

Sales CAGR 3Y: +21.3%
Profit CAGR 3Y: +226.8%
EPS CAGR 3Y: +224.5%
ROE: 15.1%

Net profitSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
1,197	1,456	1,660	2,137
–	+21.7%	+14.0%	+28.7%
1,021	1,156	1,249	1,503
176	301	412	634
14.7%	20.6%	24.8%	29.7%
24	27.4	34.6	47
77.1	85.9	76.2	39.2
99.4	119	139	167
−7.4	−13.5	−3.9	−8.9
16.4	109	228	466
39.1%	24.2%	25.3%	25.2%
10	82.8	170	349
–	+729.0%	+105.5%	+105.1%
0.48	3.98	8.61	16.43

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore

Total assetsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
18	18.1	20.8	21.2
870	957	2,108	2,463
932	928	352	288
367	373	679	854
2,187	2,275	3,160	3,626
1,183	1,275	1,608	2,122
157	109	130	313
1.9	1.9	1.9	3.5
205	185	372	189
640	704	1,048	999
2,187	2,275	3,160	3,626

Cash flow

Yearly, ₹ crore

Cash from operationsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
219	263	314	509
−102	−192	−537	−395
−201	−95.3	301	−124
−83	−24.6	78.8	−10
−113	−182	−369	−593
106	81.4	−55.2	−83.8

Shareholding pattern

Source: NSE filings

34.5%

promoters

Promoters34.50%
Public65.50%
As of 30 Sep 2026

Quarter	Promoters	Public	Promoter change
30 Sep 2026	34.50%	65.50%	minus 0.03
30 Jun 2026	34.53%	65.47%	minus 0.08
31 Mar 2026	34.61%	65.39%	minus 0.09
31 Dec 2025	34.70%	65.30%	minus 0.24
30 Sep 2025	34.94%	65.06%	–

Major shareholders

NSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you